NCT00583024View on ClinicalTrials.gov

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2020

Study Completion Date

January 31, 2023

Conditions
Hormone Refractory Prostate Cancer
Interventions
BIOLOGICAL

ADENOVIRUS/PSA VACCINE

1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60

Trial Locations (1)

52242

Holden Comprehensive Cancer Center, Iowa City

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

David M Lubaroff

OTHER

NCT00583024 - Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter